Product/Composition:- | Nalmefene Hydrochloride |
---|---|
Strength:- | 1 mg/mL in 1 mL or 2 mL vials |
Form:- | Injectable Solution |
Reference Brands:- | Selincro(EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Nalmefene Hydrochloride, marketed as Selincro in the EU, is an 18 mg oral tablet approved for alcohol dependence. It’s a non-addictive opioid modulator offering a unique therapeutic approach. A high-potential listing for pharma B2B platforms focused on CNS and addiction treatment product portfolios, especially across European markets.
Nalmefene Hydrochloride is an opioid receptor modulator approved in the EU for reducing alcohol consumption in adults with alcohol dependence. Marketed as Selincro by Lundbeck, it is available in 18 mg oral tablet form. While not FDA-approved for alcohol dependence in the US, it has been studied as an injectable in overdose management. Nalmefene offers a novel approach to addiction treatment by modulating the brain’s reward system without the risk of dependence. For pharma B2B platforms, Nalmefene is a strategic product within the CNS and addiction therapy segments, particularly in European markets seeking evidence-based, non-narcotic alcohol dependence treatments.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications